The aim of this study was to observe whether necroptosis is involved in the process of cardiac hypertrophy induced by pressure overload. SD rats underwent transverse abdominal aortic constriction (TAC) operation for establishing cardiac hypertrophy model. The structure and function of the left ventricle of rats were evaluated via echocardiography, left ventricular mass index, the expression of markers of cardiac hypertrophy and histological detection. Real-time PCR and Western blot were used to measure the gene and protein expression of receptor interacting protein kinase 1 and 3 (RIPK1 and RIPK3, the necroptosis markers) respectively. Four weeks after TAC operation, rat model for cardiac hypertrophy was established. The experimental data showed that the gene and protein expressions of RIPK1 and RIPK3 in the rat heart hypertrophic tissues after TAC for 4 weeks were increased significantly compared with those in the sham group. HE staining showed cardiomyocytes injury and hypertrophy in the hearts of TAC rat models. By transmission electron microscope, we observed that mitochondria of cardiomyocytes were damaged seriously in the TAC models. Treatment with losartan used, the selective antagonist of angiotensinⅡtypeⅠreceptor could improve the cardiac function of TAC rats. Moreover, losartan treatment decreased the expression of RIPK1 and RIPK3 in heart tissues of TAC rats. The results suggest that necroptosis occurrs in the process of cardiac hypertrophy with pressure overload, and losartan could alleviate the cardiac hypertrophy and inhibit necroptosis.
This study aims to investigate the role of calreticulin in (CRT) pressure overload induced cardiac hypertrophy. In our study, cardiac hypertrophy was induced by left ventricular pressure overload in male SD rats subjected to transverse aortic constriction (TAC) operation. Expression of gene and protein of calreticulin, markers of cardiac hypertrophy and endoplasmic reticulum stress (ERS) were measured with real-time qPCR and Western blot respectively. Meanwhile, atorvastatin (a known ERS inhibitor) and calreticulin-specific small interference ribonucleic acid (siRNA) were used to inhibit the expression of ERS and calreticulin respectively. The experimental data demonstrated that the gene and protein levels of calreticulin, hypertrophic and ERS markers were increased significantly in the heart tissues of TAC rat models after 4 weeks. Moreover, atorvastatin administration improved the cardiac function and reduced the expression of calreticulin and ERS markers in TAC rats. In addition, cultured primary neonatal rat cardiomyocytes (NCMs) were treated with norepinephrine (NE), angiotensionⅡ (AngⅡ) or isoprenaline (ISO) to induce hypertrophic phenotype and ERS. The expression of hypertrophic markers was reduced in NCMs transfected with calreticulin-siRNA. The results suggested that calreticulin might be a promising target for the treatment of cardiac hypertrophy.